Drug Profile
Alogliptin - Takeda
Alternative Names: Alogliptin benzoate; NESINA; Nesina; SYR-322; TAK-322; VipidiaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Syrrx Inc
- Developer Takeda
- Class Antihyperglycaemics; Benzonitrile; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 14 Feb 2022 Takeda completes a phase III trial for Type-2 diabetes mellitus (In adolescents, In children, Monotherapy, Adjunctive treatment) in Brazil, Germany, Israel, Italy, Mexico, Poland and US (PO, Tablet) (NCT02856113)
- 16 Apr 2021 Phase-III development in Type-2 diabetes mellitus (In adolescents, In children, Monotherapy, Adjunctive treatment) is ongoing in USA (PO) (NCT02856113)
- 16 Apr 2021 Discontinued - Preregistration for Type 2 diabetes mellitus in Indonesia (PO)